

**Supplement to Prospectus regarding invitation to subscribe for
units in Alligator Bioscience AB (publ)**

9 May 2023



Distribution of this supplementary prospectus is restricted in certain jurisdictions,
see further in the section "Important information" in the Prospectus.

SUPPLEMENT TO THE PROSPECTUS

This document (the "**Supplement Prospectus**") has been prepared by Alligator Bioscience AB, corporate registration number 556597-8201 ("**Alligator**" or the "**Company**"), and constitutes a supplement to the Prospectus regarding the invitation to subscribe for units in Alligator (the "**Rights Issue**") as approved and registered by the Swedish Financial Supervisory Authority on 26 April 2023 (Swedish Financial Supervisory Authority reference number 23-2847) (the "**Prospectus**"). The Supplement Prospectus is to be considered a part of, and shall be read in connection with, the Prospectus. The definitions set forth in the Prospectus shall have the same meaning for the Supplement Prospectus. The Prospectus and the Supplement Prospectus have been prepared in a Swedish and an English language version, respectively. In the event of any inconsistencies between the language versions, the Swedish language version shall prevail.

The Supplement Prospectus has been prepared as the Company has noted two errors in the Prospectus, partly regarding the number of warrants series TO 6 that entitle to subscription of new ordinary shares in the Company at one place in the summary of the Prospectus, and partly regarding the percentage for the guarantee remuneration that is paid to top guarantors under the section "Transactions with related parties".

The Supplement Prospectus has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "**Prospectus Regulation**") and was approved by the Swedish Financial Supervisory Authority on 9 May 2023 (Swedish Financial Supervisory Authority reference number 23-13859). The Supplement Prospectus was published by the Company on the same day.

Investors who, prior to the publication of the Supplement Prospectus, have applied or in any other way consented to subscription of units in the Rights Issue have, according to Article 23 in the Prospectus Regulation, the right to withdraw their application or consent within two business days from the publication of the Supplementary Prospectus, i.e. until and including 11 May 2023. Withdrawal shall be made in writing to Aktieinvest FK AB, Emittentservice, P.O. Box 7415, SE-103 91 Stockholm, Sweden, or via email to emittentservice@aktieinvest.se. Investors who have applied for subscription of units through a nominee shall contact their nominee regarding withdrawal. Application which is not withdrawn within said time will remain binding and investors who wish to keep their application for units do not need to take any actions.

The Prospectus and the Supplement Prospectus are made available on the Company's, Aktieinvest FK AB's and Redeye AB's respective websites (www.alligatorbioscience.com, www.aktieinvest.se and www.redeye.se). The Prospectus and the Supplement Prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). For complete terms and conditions and other information regarding the Rights Issue, please refer to the Prospectus.

SUPPLEMENT TO SECTION “SUMMARY”

In the summary under section “*Key information on the Rights Issue*” and the sub-section “*Under which conditions and timetable can I invest in this security?*” on page 8 in the Prospectus, changes shall be made in accordance with the italic text below under section “*Warrants*” in the first sentence:

The warrants that are issued in the Rights Issue are issued free of charge and each warrant series TO 6 entitles the holder to subscribe for *ordinary shares in the Company* during the period 17 August – 31 August 2023. *Eight (8) warrants series TO 6 entitle to subscription of one (1) new ordinary share in Alligator* against cash consideration amounting to 70 per cent of the volume-weighted average share price of the Company’s share on Nasdaq Stockholm during the period 1 August – 14 August 2023, however not less than SEK 0.40.

SUPPLEMENT TO SECTION “LEGAL CONSIDERATIONS AND SUPPLEMENTARY INFORMATION”

Under section “*Transactions with related parties*” on page 80 in the Prospectus, changes shall be made in accordance with the italic text below in the third paragraph, third sentence:

For the guarantee commitments, cash compensation of eleven (11) per cent of the guaranteed amounts is paid for the bottom guarantee, and of *fourteen (14)* per cent of the guaranteed amount for the top guarantees.